Hims & Hers Reports High Success Rate in GLP-1 Program
A new white paper from Hims & Hers reveals that 87% of customers are working toward, nearing, or have already met their weight loss goal
Hims & Hers Health, Inc. has released a white paper, “Hims & Hers Weight Loss: A Look at Early Customer Experiences and Outcomes,” providing insight into the success of compounded medication users within the Hims & Hers weight loss program.
Early findings show that customers are managing side effects well and feeling healthier overall. 79% of compounded GLP-1 customers reveal their experience has met or surpassed their expectations. A high number (90%) report they are satisfied with their personalized dosing plan, and 87% of customers are working toward, nearing, or have already met their weight loss goal.
“The data and insights we have been able to glean through our research show that our customers are having meaningful health outcomes when it comes to weight loss,” said Dr. Jessica Yu, senior director of patient experience at Hims & Hers. “The data shows our customers are experiencing good weight loss on compounded medications, having manageable side-effects through personalized dosing, suggesting the treatment is sustainable and they are making positive strides towards a healthier future.”
Other findings demonstrate that, on average, those using oral medication kits lost 7.5 pounds within their first month – approximately 3.6% of their initial body weight. Those using compounded GLP-1s lost an average of 9.3 pounds (approximately 4.1% of their initial body weight) in their first month.
“The importance of these findings is significant as we believe early customer satisfaction and treatment adherence is likely to enhance long-term outcomes and even more important as we continue to search for ways to manage the obesity crisis in our nation,” Dr. Yu continued.
Dr. Patrick Carroll, chief medical officer of Hims & Hers, noted that the company is laser-focused on increasing access to personalized care in the highest impact areas of health and fitness.
“With over 40% of our nation’s adults considered obese, our country demands that we use our expertise, size, and industry leadership to answer the very real obesity crisis in the United States and be a part of the solution for the millions of Americans who have obesity and are looking for help,” Carroll said.
A KFF Health Tracking Poll found that roughly one in eight adults had taken a GLP-1 agonist earlier this year. With a growing supply and rising consumer demand, BMO Capital Markets anticipates that annual sales of weight-loss drugs could soar to $150 billion by 2033, surpassing earlier projections.
“Hims & Hers Weight Loss: A Look at Early Customer Experiences and Outcomes,” can be found here.
